User contributions
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 13:30, 9 December 2019 (diff | hist) . . (-64) . . m Rituximab and hyaluronidase human (Rituxan Hycela) (current)
- 13:28, 9 December 2019 (diff | hist) . . (+550) . . m Category:Chemotherapeutic (current)
- 21:31, 8 December 2019 (diff | hist) . . (+1,460) . . m Complex multipart regimens (→Kümmel et al. 2006) (current)
- 21:30, 8 December 2019 (diff | hist) . . (-1,430) . . m Complex multipart regimens (→Amadori et al. 2010)
- 08:58, 8 December 2019 (diff | hist) . . (+4) . . m Breast cancer, PIK3CA-mutated (→Regimen {{#subobject:31ed8c|Variant=1}}) (current)
- 08:57, 8 December 2019 (diff | hist) . . (+488) . . m Ovarian cancer - historical (current)
- 21:36, 7 December 2019 (diff | hist) . . (+812) . . m B-cell acute lymphoblastic leukemia (current)
- 20:04, 7 December 2019 (diff | hist) . . (+4) . . m Soft tissue sarcoma - historical (→Doxorubicin & Olaratumab {{#subobject:31132d|Regimen=1}}) (current)
- 20:03, 7 December 2019 (diff | hist) . . (+837) . . m Soft tissue sarcoma (current)
- 15:55, 7 December 2019 (diff | hist) . . (+212) . . m Opioid Conversion Table (current)
- 15:44, 7 December 2019 (diff | hist) . . (+1,286) . . m Ovarian cancer (current)
- 15:23, 7 December 2019 (diff | hist) . . (+290) . . m Atezolizumab (Tecentriq) (→Non-small cell lung cancer) (current)
- 15:22, 7 December 2019 (diff | hist) . . (+194) . . m Non-small cell lung cancer (→Carboplatin, nab-Paclitaxel, Atezolizumab {{#subobject:7a8cn7|Regimen=1}}) (current)
- 14:45, 7 December 2019 (diff | hist) . . (+1,534) . . m Ovarian cancer (→Carboplatin & Paclitaxel {{#subobject:dd35ee|Regimen=1}})
- 14:33, 7 December 2019 (diff | hist) . . (+35) . . m Links to companies with oncology-specific products (→Other) (current)
- 14:33, 7 December 2019 (diff | hist) . . (+35) . . m Vesicant & irritant chemotherapy (→Reference) (current)
- 14:31, 7 December 2019 (diff | hist) . . (+35) . . m Opioid Conversion Table (→Morphine : Methadone have a dose based adjustment)
- 14:31, 7 December 2019 (diff | hist) . . (+35) . . m Inherited thrombophilia (→All lines of therapy) (current)
- 14:31, 7 December 2019 (diff | hist) . . (+35) . . m Inherited coagulopathy (→Factor IX deficiency (Hemophilia B), all lines of therapy) (current)
- 14:31, 7 December 2019 (diff | hist) . . (+35) . . m Immune thrombocytopenia (→Vinblastine-loaded platelets) (current)
- 14:30, 7 December 2019 (diff | hist) . . (+35) . . m Immunotherapy toxicity management (→References) (current)
- 14:30, 7 December 2019 (diff | hist) . . (+35) . . m Hypereosinophilic syndrome (→References) (current)
- 14:30, 7 December 2019 (diff | hist) . . (+35) . . m Hypercoagulable state (thrombophilia) (→References) (current)
- 14:30, 7 December 2019 (diff | hist) . . (+35) . . m Eosinophilia (→Evaluation) (current)
- 14:29, 7 December 2019 (diff | hist) . . (+35) . . m Bleeding disorders and risk (→References) (current)
- 14:29, 7 December 2019 (diff | hist) . . (+35) . . m Basics of Pain Management (→References) (current)
- 14:29, 7 December 2019 (diff | hist) . . (+35) . . m Autoimmune cytopenia (→Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}) (current)
- 14:28, 7 December 2019 (diff | hist) . . (+35) . . m Antiphospholipid antibody syndrome (→References) (current)
- 14:28, 7 December 2019 (diff | hist) . . (+35) . . m Anemia (current)
- 13:56, 7 December 2019 (diff | hist) . . (+107) . . m Hairy cell leukemia (current)
- 14:23, 6 December 2019 (diff | hist) . . (+1,061) . . m Multiple myeloma, relapsed-refractory (→PD {{#subobject:06b435|Regimen=1}}) (current)
- 14:18, 6 December 2019 (diff | hist) . . (+703) . . m Isatuximab (SAR-650984) (→Preliminary data) (current)
- 17:07, 5 December 2019 (diff | hist) . . (+1,268) . . m Hodgkin lymphoma (current)
- 23:15, 4 December 2019 (diff | hist) . . (+70) . . m Essential thrombocythemia (current)
- 20:49, 4 December 2019 (diff | hist) . . (+56) . . m NovoTTF-100A system (Optune) (current)
- 20:48, 4 December 2019 (diff | hist) . . (+1,413) . . Mesothelioma (→Cisplatin, Pemetrexed, Bevacizumab {{#subobject:f3f261|Regimen=1}}) (current)
- 13:53, 4 December 2019 (diff | hist) . . (+65) . . m Uveal melanoma (current)
- 13:51, 4 December 2019 (diff | hist) . . (+34) . . m Periampullary adenocarcinoma (current)
- 13:48, 4 December 2019 (diff | hist) . . (+232) . . m Osteosarcoma (current)
- 08:05, 4 December 2019 (diff | hist) . . (+116) . . m Adenocarcinoma of unknown primary (current)
- 08:02, 4 December 2019 (diff | hist) . . (+1,217) . . m Aplastic anemia (current)
- 23:01, 3 December 2019 (diff | hist) . . (+97) . . m Hepatocellular carcinoma - historical (current)
- 22:58, 3 December 2019 (diff | hist) . . (+86) . . m Hepatoblastoma (current)
- 22:53, 3 December 2019 (diff | hist) . . (+193) . . m CNS melanoma (→Ipilimumab & Nivolumab {{#subobject:28103f|Regimen=1}}) (current)
- 21:06, 3 December 2019 (diff | hist) . . (+706) . . m Prostate cancer (→Goserelin & RT {{#subobject:88575c |Regimen=1}}) (current)
- 21:03, 3 December 2019 (diff | hist) . . (+2,513) . . Non-small cell lung cancer, EGFR-mutated (→Advanced or metastatic disease, EGFR inhibitor-naive) (current)
- 16:45, 3 December 2019 (diff | hist) . . (+3,616) . . m Merkel cell carcinoma (→Avelumab monotherapy {{#subobject:41b46c|Regimen=1}}) (current)
- 22:38, 2 December 2019 (diff | hist) . . (+290) . . m Follicular lymphoma - historical (current)
- 22:26, 2 December 2019 (diff | hist) . . (+700) . . m Chronic lymphocytic leukemia - historical (current)
- 22:07, 2 December 2019 (diff | hist) . . (-57) . . m Renal cell carcinoma - historical (current)
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
